TSXV:PTQ

Stock Analysis Report

Protech Home Medical

Executive Summary

Protech Home Medical Corp. provides and rents in-home monitoring equipment and services for patients in the United States.

Snowflake

Fundamentals

Adequate balance sheet with concerning outlook.

Share Price & News

How has Protech Home Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

8.9%

PTQ

0.7%

CA Healthcare

0.2%

CA Market


1 Year Return

22.9%

PTQ

-7.2%

CA Healthcare

2.4%

CA Market

Return vs Industry: PTQ exceeded the Canadian Healthcare industry which returned -7.2% over the past year.

Return vs Market: PTQ exceeded the Canadian Market which returned 2.4% over the past year.


Shareholder returns

PTQIndustryMarket
7 Day8.9%0.7%0.2%
30 Day1.2%-0.8%-3.3%
90 Day11.7%-7.7%-1.8%
1 Year22.9%22.9%-4.5%-7.2%6.0%2.4%
3 Yearn/a-1.1%-14.8%14.2%4.0%
5 Yearn/a55.0%16.0%27.2%8.6%

Price Volatility Vs. Market

How volatile is Protech Home Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Protech Home Medical undervalued compared to its fair value and its price relative to the market?

4.6x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: PTQ (CA$0.86) is trading above our estimate of fair value (CA$0.13)

Significantly Below Fair Value: PTQ is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PTQ is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.

PE vs Market: PTQ is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTQ is overvalued based on its PB Ratio (4.6x) compared to the CA Healthcare industry average (2.4x).


Next Steps

Future Growth

How is Protech Home Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

19.2%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PTQ's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if PTQ's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: PTQ's revenue (19.2% per year) is forecast to grow faster than the Canadian market (5.5% per year).

High Growth Revenue: PTQ's revenue (19.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTQ's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Protech Home Medical performed over the past 5 years?

-10.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: PTQ is unprofitable, and losses have increased over the past 5 years at a rate of -10.5% per year.

Accelerating Growth: Unable to compare PTQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTQ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-46%).


Return on Equity

High ROE: PTQ has a negative Return on Equity (-211.39%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: PTQ is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: PTQ is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Protech Home Medical's financial position?


Financial Position Analysis

Short Term Liabilities: PTQ's short term assets (CA$27.2M) exceeds its short term liabilities (CA$19.1M)

Long Term Liabilities: PTQ's short term assets (27.2M) exceeds its long term liabilities (16.8M)


Debt to Equity History and Analysis

Debt Level: PTQ's debt to equity ratio (86.2%) is considered high

Reducing Debt: PTQ's debt to equity ratio has increased from 7.3% to 86.2% over the past 5 years.


Balance Sheet

Inventory Level: PTQ has a high level of physical assets or inventory.

Debt Coverage by Assets: PTQ's debt is covered by short term assets (assets are 2.019450x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable PTQ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: PTQ is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 96.6% per year.


Next Steps

Dividend

What is Protech Home Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate PTQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PTQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if PTQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTQ's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Protech Home Medical's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Greg Crawford 0

1.8yrs

Tenure

CA$1,286,117

Compensation

Mr. Gregory J. Crawford also known as Greg, has been Chief Executive Officer President and Director of Protech Home Medical Corp. (also known as Patient Home Monitoring Corp.) ("PHM") since December 21, 20 ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Greg's total compensation is reasonable compared to companies of similar size in the Canadian market.

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

49yo

Average Age

Experienced Management: PTQ's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

3.9yrs

Average Tenure

Experienced Board: PTQ's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$131,00002 Nov 18
D. Ewing
EntityIndividual
Role
Member of the Board of Directors
Non-Executive Director
Shares218,333.2
Max PriceCA$0.60
BuyCA$300,00102 Nov 18
Hardik Mehta
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares500,000
Max PriceCA$0.60
BuyCA$669,00202 Nov 18
Gregory Crawford
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares1,115,000
Max PriceCA$0.60

Ownership Breakdown


Management Team

  • Thomas Roehrig (53yo)

    Executive Vice President of Finance

    • Tenure: 0.08yrs
  • Robbie Grossman (45yo)

    Corporate Secretary

    • Tenure: 0yrs
  • Leslie Becker

    Executive Vice President of Business Development

    • Tenure: 8.4yrs
  • W. Zehnder (44yo)

    Chief Strategy Officer & Investor Relations

    • Tenure: 0yrs
    • Compensation: CA$308.24k
  • Greg Crawford

    Chairman

    • Tenure: 1.8yrs
    • Compensation: CA$1.29m
  • William Frazier (61yo)

    Chief Medical Officer

    • Tenure: 4yrs
  • Hardik Mehta

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: CA$1.15m
  • Jerry Kirn

    Vice President of Operations

    • Tenure: 0yrs
  • Mark Miles

    Vice President of Technology

    • Tenure: 0yrs

Board Members

  • Mark Greenberg

    Director

    • Tenure: 1.8yrs
    • Compensation: CA$695.98k
  • Gene Ewing (70yo)

    Non-Executive Director

    • Tenure: 1.2yrs
    • Compensation: CA$115.33k
  • Steven Axelrod

    Member of the Board of Advisors

    • Tenure: 6yrs
  • Jim Booth

    Member of the Board of Advisors

    • Tenure: 6yrs
  • Greg Crawford

    Chairman

    • Tenure: 1.8yrs
    • Compensation: CA$1.29m

Company Information

Protech Home Medical Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protech Home Medical Corp.
  • Ticker: PTQ
  • Exchange: TSXV
  • Founded: 1993
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: CA$71.835m
  • Shares outstanding: 83.53m
  • Website: https://www.protechhomemedical.com

Location

  • Protech Home Medical Corp.
  • 1019 Town Drive
  • Wilder
  • Kentucky
  • 41076
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTQTSXV (TSX Venture Exchange)YesNew Common SharesCACADDec 2017
1P4DB (Deutsche Boerse AG)YesNew Common SharesDEEURDec 2017
PHMZ.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDDec 2017

Biography

Protech Home Medical Corp. provides and rents in-home monitoring equipment and services for patients in the United States. It offers daily and ambulatory aides; power mobility equipment; INR self-testing e ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:50
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.